<DOC>
	<DOCNO>NCT01664052</DOCNO>
	<brief_summary>This study design evaluate investigational model Essure System Permanent Birth Control . The investigational device design offer advantage currently approve device . In addition , investigational device offer immediate , permanent contraception without three-month wait period 90-day confirmation test . This study design evaluate effectiveness investigational device cause tubal occlusion insert placement three month wear .</brief_summary>
	<brief_title>ESS505 Pre-hysterectomy Protocol</brief_title>
	<detailed_description>This study previously post Conceptus , Inc. ( US ) . After acquire Conceptus , Inc. , Bayer HealthCare AG ( Germany ) sponsor trial .</detailed_description>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Terephthalic acid</mesh_term>
	<criteria>Subjects schedule undergo Laparoscopically Assisted Vaginal Hysterectomy ( LAVH ) , Total Abdominal Hysterectomy ( TAH ) , Total Vaginal Hysterectomy ( TVH ) , Total Laparoscopic Hysterectomy ( TLH ) Bilateral Total Salpingectomy Bilateral Salpingooophorectomy ( BSO ) , Laparoscopic Supracervical Hysterectomy ( LSH ) Subjects 18 year age old Subjects able willing provide write informed consent Subjects agree use contraceptive method follow Essure placement hysterectomy procedure Subjects bilateral proximal tubal occlusion Subjects undergone fallopian tube sterilization Subjects know endometrial myometrial pathology likely prevent access fallopian tube ostia Subjects postmenopausal Subjects pelvic inflammatory disease ( PID ) Subjects gynecologic malignancy Pregnancy suspect pregnancy Delivery termination pregnancy le 6 week Essure microinsert placement Known allergy contrast medium Any general health condition may represent , opinion Investigator , increase potential risk associate participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>